Concord Drugs Limited reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported sales was INR 134.42 million compared to INR 82.41 million a year ago. Revenue was INR 134.69 million compared to INR 82.47 million a year ago. Net income was INR 4.21 million compared to INR 26.98 million a year ago. Basic earnings per share from continuing operations was INR 0.482 compared to INR 3.09 a year ago. Diluted earnings per share from continuing operations was INR 0.482 compared to INR 3.09 a year ago.
For the nine months, sales was INR 434.92 million compared to INR 430.11 million a year ago. Revenue was INR 435.69 million compared to INR 430.84 million a year ago. Net income was INR 15.67 million compared to INR 29.45 million a year ago. Basic earnings per share from continuing operations was INR 1.792. Diluted earnings per share from continuing operations was INR 1.79.